Premature Birth of Newborn
2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Elgan PharmaIsrael - Nazareth
2 programs1
1
NTRA-2112Phase 31 trial
Oral Formulation of InsulinPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Elgan PharmaNTRA-2112
Elgan PharmaOral Formulation of Insulin
Angeles TherapeuticsFamily Integrated Care
Clinical Trials (3)
Total enrollment: 680 patients across 3 trials
Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants
Start: Oct 2016Est. completion: Apr 2018300 patients
Phase 3Terminated
Oral Formulation of Insulin for Preterm Infants
Start: Aug 2010Est. completion: Jan 201633 patients
Phase 2Terminated
Improving Preterm Infant Outcomes With Family Integrated Care and Mobile Technology
Start: Apr 2017Est. completion: Mar 2021347 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.